MEDS Revenue and Competitors
Estimated Revenue & Valuation
- MEDS's estimated annual revenue is currently $16M per year.
- MEDS's estimated revenue per employee is $140,000
Employee Data
- MEDS has 114 Employees.
- MEDS grew their employee count by -4% last year.
MEDS's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-founder and CTO at MEDS | Reveal Email/Phone |
2 | Founder and CEO | Reveal Email/Phone |
3 | Head Performance | Reveal Email/Phone |
4 | Head Technology | Reveal Email/Phone |
5 | Category Manager | Reveal Email/Phone |
6 | Category Manager | Reveal Email/Phone |
7 | Group financial controller | Reveal Email/Phone |
8 | System developer | Reveal Email/Phone |
9 | Developer | Reveal Email/Phone |
10 | Operative Purchaser | Reveal Email/Phone |
MEDS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.5M | 12 | 50% | N/A | N/A |
What Is MEDS?
MEDS delivers within hours from order straight to the door in Stockholm and same day in many parts of Sweden
keywords:N/AN/A
Total Funding
114
Number of Employees
$16M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MEDS News
2022-04-19 - US meds spending spiked last year, but will fall quickly -
Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Without that...
2022-04-17 - April 2022: Kaplan MCAT stumpers put pre-meds to the test
For students preparing for medical school, the AMA pre-med glossary guide has the answers to frequently asked questions.
2022-04-17 - Fetal exposure to meds may affect infants' brain development
Fetal exposure to meds may affect infants' brain development. Date: April 20, 2022; Source: University of Helsinki; Summary: A new study demonstrates that...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $23M | 114 | 6% | N/A |
#2 | $22.9M | 114 | -67% | N/A |
#3 | $29M | 114 | 24% | N/A |
#4 | N/A | 114 | 56% | N/A |
#5 | $17.1M | 114 | 25% | N/A |